Fujitsu Ltd: Fujitsu, Kyoto University, and Chordia Therapeutics launch AI trials to discover biomarkers for new cancer drugs

TOKYO, May 17, 2023 - (JCN Newswire) - Fujitsu Limited, Kyoto University (1), Chordia Therapeutics, Inc. (2), today announced the beginning of field trials leveraging Fujitsu's AI causal discovery technology

Related Keywords

Sakyo Ku ,Kyoto ,Japan ,Tokyo ,Kanagawa ,Fukushima ,Hiroshi Miyake ,Daisuke Morishita ,Minato Nagahiro ,Gewinn Nur ,Seishi Okamoto ,Seishi Ogawa ,Shonan Health Innovation Park ,School Of Medicine ,Kyoto University ,Innovation Institute ,Fujitsu Ltd ,Fujitsu ,Investor Relations Division ,Kyoto University Open Innovation Institute ,Chordia Therapeutics Inc ,Kyoto University Group ,Head Of Fujitsu Research ,Fujitsu Limited ,Chordia Therapeutics ,Graduate School ,Fujitsu Research ,Kyoto City ,Kyoto Prefecture ,Fujisawa City ,Kanagawa Prefecture ,Open Innovation Institute ,Society Academia Collaboration ,Innovation Work ,Converging Technologies ,University ,Chordia ,Herapeutics ,Launch ,Trials ,Discover ,Biomarkers ,Dancer ,Drugs ,